Momenta Pharmaceuticals Inc (MNTA)

15.80
0.50 3.27
NASDAQ : Health Care
Prev Close 15.30
Open 15.40
Day Low/High 15.40 / 15.85
52 Wk Low/High 7.86 / 23.62
Volume 348.23K
Avg Volume 720.50K
Exchange NASDAQ
Shares Outstanding 76.23M
Market Cap 1.17B
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

March 2018 Options Now Available For Momenta Pharmaceuticals (MNTA)

Investors in Momenta Pharmaceuticals Inc saw new options begin trading today, for the March 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Momenta Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Momenta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $17.00, changing hands for $17.25/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Momenta Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Momenta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $17.00, changing hands for $17.05/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..

Momenta Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for MNTA

In trading on Tuesday, shares of Momenta Pharmaceuticals Inc crossed above their 200 day moving average of $13.55, changing hands as high as $13.80 per share. Momenta Pharmaceuticals Inc shares are currently trading up about 3% on the day.

Oversold Conditions For Momenta Pharmaceuticals (MNTA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of May 19th Options Trading For Momenta Pharmaceuticals (MNTA)

Investors in Momenta Pharmaceuticals Inc saw new options begin trading this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

Notable Two Hundred Day Moving Average Cross - MNTA

In trading on Tuesday, shares of Momenta Pharmaceuticals Inc crossed below their 200 day moving average of $13.28, changing hands as low as $13.18 per share. Momenta Pharmaceuticals Inc shares are currently trading off about 5.4% on the day.

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Momenta Pharmaceuticals, Inc., And Encourages Investors To Contact The Firm

Khang & Khang LLP (the "Firm") announces that it is investigating claims against Momenta Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving The Board Of Momenta Pharmaceuticals, Inc. -- MNTA

Levi & Korsinsky announces it has commenced an investigation of Momenta Pharmaceuticals, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABMD, ABX, AEM, BGG, BIIB, HBM, HTBI, KALU, MNTA, NEWM, NQ, SNE, VMI, VPG, WMT, XCRA Downgrades: CGNX, DAKT, EXAC, FSLR, HOLI, PFLT Initiations: AGR Read on to get TheStreet Quant Ratings' detailed report:

Analysts' Actions -- Discovery, First Solar, Momenta, VF Corp. and More

Analysts' Actions -- Discovery, First Solar, Momenta, VF Corp. and More

Here are Wednesday's top research calls, including downgrades for Discovery, First Solar and Momenta, and an upgrade for VF Corp.

Sarepta Leads Biotech Movers on Voucher Deal News

Sarepta Leads Biotech Movers on Voucher Deal News

Gilead (finally!) has acquired something from Sarepta, even if it is quite small.